-
Stocks in Focus: Intercept Pharmaceuticals (NASDAQ:ICPT), Itau Unibanco Holding SA (ADR) (NYSE:ITUB), Interface Inc. (NASDAQ:TILE), Empresa Nacional (NYSE:EOC), HNI Corp. (NYSE:HNI)
On Nov. 6, Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) reported financial results for the quarter and nine months ended September 30, 2014 and provided other general business updates. For the nine months ended September 30, 2014 and 2013, Intercept reported a net loss of $248.4 million and $55.4 million, respectively. Included in the net loss were non-cash…
-
Active Stocks: The TJX Companies (NYSE:TJX), Intercept Pharmaceuticals (NASDAQ:ICPT), Shaw Communications (NYSE:SJR), Electro Rent Corporation (NASDAQ:ELRC), Royale Energy (NASDAQ:ROYL)
The TJX Companies Inc. (NYSE:TJX) will post its quarterly earnings results on Tuesday, November 18th. The TJX Companies has set its Q3 guidance at $0.81-0.85 EPS and its FY15 guidance at $3.10-3.18 EPS. The TJX Companies, Inc. (NYSE:TJX) in last trading activity decreased -1.25% to close at $61.54. Company weekly performance is -3.72% while its…
-
Mid Cap Losers: Transocean (NYSE:RIG), Rice Energy Inc. (NYSE:RICE), Intercept Pharmaceuticals (NASDAQ:ICPT), Synchronoss Technologies (NASDAQ:SNCR), Tahoe Resources Inc. (NYSE:TAHO)
Transocean Ltd. (NYSE:RIG) on 10 October reported third-quarter earnings that, excluding a one-time writedown in the value of its drilling rigs, beat analysts’ estimates because of cost-cutting efforts. The owner of the biggest fleet of deep-water drilling rigs delayed publishing earnings last week after announcing more than $2 billion in writedowns because of an oversupply…
-
Drug Most Active Stocks: Pfizer Inc. (NYSE:PFE), Merck & Co. Inc. (NYSE:MRK), Intercept Pharmaceuticals (NASDAQ:ICPT), Immune Pharmaceuticals (NASDAQ:IMNP), KaloBios Pharmaceuticals (NASDAQ:KBIO)
Pfizer Inc. (NYSE:PFE) announced that it will present data for several of its marketed and investigational medicines for inflammatory and immunological conditions at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2014 Annual Meeting (November 14-19, Boston, Massachusetts). Twenty-one abstracts for XELJANZ® (tofacitinib citrate) will be presented, including the six-year…
-
Mid Cap Losers: Salix Pharmaceuticals (NASDAQ:SLXP), Intercept Pharmaceuticals (NASDAQ:ICPT), Extended Stay America (NYSE:STAY), Ubiquiti Networks (NASDAQ:UBNT), Agios Pharmaceuticals (NASDAQ:AGIO)
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Salix Pharmaceuticals Ltd. (NASDAQ:SLXP).Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) in last trading activity decreased -33.98% to close at $91.47. Company weekly performance is -36.41% while its…
-
Top News: Intercept Pharmaceuticals (NASDAQ:ICPT), Twitter Inc (NYSE:TWTR), Genworth Financial (NYSE:GNW), Smart & Final Stores (NYSE:SFS), Alibaba Group NYSE:BABA)
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) CEO Mark Pruzanski sold 10,000 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $259.41, for a total value of $2,594,100.00. Following the completion of the transaction, the chief executive officer now directly owns 479,909 shares in the…
-
Gainers on major news – Macy’s (NYSE:M),Intercept Pharmaceuticals (NASDAQ:ICPT), Delta Air Lines (NYSE:DAL), Costco Wholesale (NASDAQ:COST)
Macy’s Inc. forecast profit for its next fiscal year that is higher than analysts estimate and said it would cut 2,500 jobs to reduce costs. Shares of Macy’s, Inc. (NYSE:M) closed at $55.80 in last trading session. Yesterday share price of the company was traded in the range of $54.79 to $56.25. Company now has…